BMC Cardiovascular Disorders (Jan 2025)
Association of elevated albumin-corrected anion gap with all-cause mortality risk in atrial fibrillation: a retrospective study
Abstract
Abstract Background Compared to the conventional anion gap, the albumin-corrected anion gap (ACAG) offers a more precise measure of acid-base imbalance, providing superior prognostic insight. However, the prognostic relevance of ACAG in individuals of atrial fibrillation (AF) remains insufficiently explored. This research seeks to evaluate the correlation between ACAG levels and mortality risk in individuals with AF. Methods We identified individuals diagnosed with AF from the Medical Information Mart for Intensive Care (MIMIC)-IV database. Participants were categorized into quartiles based on their ACAG levels. The outcomes included 30 days and 365 days all-cause mortality. Kaplan–Meier survival curves were utilized to evaluate cumulative survival across the ACAG quartiles. We applied Cox regression and restricted cubic spline regression analyses to evaluate the correlation between ACAG levels and prognosis. Subgroup analyses and interaction assessments were applied to confirm the robustness of the findings. Results A total of 2920 AF patients (54.93% male) were incorporated into the analysis, with 1.61% identified as having paroxysmal AF. The 30-day and 365-day mortality rates were 22.91% and 39.21%, respectively. Kaplan–Meier survival curves demonstrated that elevated ACAG levels were significantly linked to increased mortality (log-rank P 0.05). Conclusions In individuals with AF, higher ACAG levels are related to a greater mortality risk at 30 and 365 days. These findings suggest that ACAG may serve as a valuable prognostic marker for AF patient stratification. Incorporating ACAG into clinical decision-making could support improved therapeutic strategies and enhance patient outcomes.
Keywords